Is Neurocrine Biosciences Inc (NBIX) overvalued? · P/E 45, rev $2.36B
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
This page asks whether Neurocrine Biosciences Inc (NBIX) looks expensive on cached numbers — not a short thesis.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next NBIX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the NBIX stock page for the full model, not this heading.
Not investment advice.